Status:
COMPLETED
Development of a Model to Predict Progression-Free Survival After Erlotinib in Patients With Non-Small Cell Lung Cancer
Lead Sponsor:
ECOG-ACRIN Cancer Research Group
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Lung Cancer
Eligibility:
All Genders
Up to 120 years
Brief Summary
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also hel...
Detailed Description
OBJECTIVES: * Assess mesenchymal and epithelial markers in tissues from patients with non-small cell lung cancer treated with erlotinib hydrochloride on clinical trial ECOG-E3503. * Determine the los...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Diagnosis of non-small cell lung cancer, including any of the following subtypes:
- Adenocarcinoma
- Squamous cell carcinoma
- Bronchoalveolar carcinoma
- Carcinoid
- Stage IIIB or IV or recurrent disease
- Must have received treatment with erlotinib hydrochloride on clinical trial ECOG-E3503
- PATIENT CHARACTERISTICS:
- Not specified
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Exclusion
Key Trial Info
Start Date :
April 13 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 13 2008
Estimated Enrollment :
137 Patients enrolled
Trial Details
Trial ID
NCT00897533
Start Date
April 13 2007
End Date
April 13 2008
Last Update
May 19 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.